Development

Therapeutic
Radiopharmaceuticals

NorthStar Medical Radioisotopes is poised to become the first-in-class supply chain for the future of therapeutic radiopharmaceuticals.  Check back for progress on our non-carrier-added (n.c.a) Ac-225 and Cu-67 development programs.

Therapeutic
Radiopharmaceuticals

Therapeutic radiopharmaceuticals are comprised of a therapeutic radioisotope and a targeting molecular carrier that delivers the radioactive drug selectively TO CANCER CELLS, LEAVING HEALTHY CELLS INTACT.

Radioisotopes that decay by beta-particle (negatively charged electrons) or alpha-particle (helium nuclei) emissions are selected for these radiotherapeutics as they can deliver lethal radiation to tumor sites during their radioactive decay. The molecular carriers, such as monoclonal antibodies or peptides, target a specific site on a tumor cell and are designed for high tumor uptake. The radioisotopes are bound to the carrier molecules with a chemical linker to ensure the radionuclide remains attached to the molecule in the bloodstream and is carried to the tumor site to deliver their therapeutic dose. The graphic below demonstrates this process.